Patients treated with everolimus and metformin for at least nine weeks had a prolonged survival compared with those who had to discontinue study treatment prematurely due to toxicity, but these analyses were conducted in very small groups and should be carefully considered as merely preliminary evidence of anti-tumor efficacy of the combination of an mTOR inhibitor and a biguanide. This evidence concerns the gene MTOR and neoplasm.